Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2015 4
2016 4
2017 5
2018 4
2020 3
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease.
Zorzi F, Calabrese E, Monteleone I, Fantini M, Onali S, Biancone L, Pallone F, Monteleone G. Zorzi F, et al. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7. doi: 10.1111/apt.12051. Aliment Pharmacol Ther. 2012. PMID: 22971085 Free article. Clinical Trial.
AIM: Since TGF-beta1 has pro-fibrogenic effects in many organs, we evaluated whether GED0301 treatment associates with the formation of small bowel strictures. ...Seven of 12 patients who reached clinical remission following GED0301 treatment maintained a CDAI < …
AIM: Since TGF-beta1 has pro-fibrogenic effects in many organs, we evaluated whether GED0301 treatment associates with the formation …
TGF-Beta signaling manipulation as potential therapy for IBD.
Marafini I, Zorzi F, Codazza S, Pallone F, Monteleone G. Marafini I, et al. Curr Drug Targets. 2013 Nov;14(12):1400-4. doi: 10.2174/13894501113149990157. Curr Drug Targets. 2013. PMID: 23489130 Review.
Altogether these observations led to the development of an oral pharmaceutical compound containing the specific Smad7 antisense oligonucleotide (herein termed GED0301), which seems to be safe and well tolerated in CD patients. In this article we summarize the data supporti …
Altogether these observations led to the development of an oral pharmaceutical compound containing the specific Smad7 antisense oligonucleot …
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease.
Monteleone G, Fantini MC, Onali S, Zorzi F, Sancesario G, Bernardini S, Calabrese E, Viti F, Monteleone I, Biancone L, Pallone F. Monteleone G, et al. Mol Ther. 2012 Apr;20(4):870-6. doi: 10.1038/mt.2011.290. Epub 2012 Jan 17. Mol Ther. 2012. PMID: 22252452 Free PMC article. Clinical Trial.
No serious adverse event was registered. GED0301 was well tolerated and no patient dropped out during the study. ...The study shows for the first time that GED0301 is safe and well tolerated in patients with active CD....
No serious adverse event was registered. GED0301 was well tolerated and no patient dropped out during the study. ...The study shows f …
Oral SMAD7 antisense drug for Crohn's disease.
Vermeire S. Vermeire S. N Engl J Med. 2015 Mar 19;372(12):1166-7. doi: 10.1056/NEJMe1415053. N Engl J Med. 2015. PMID: 25785975 No abstract available.
23 results